Tempest Therapeutics Stock Three Year Return
| TPST Stock | USD 0.95 0.01 1.04% |
Tempest Therapeutics fundamentals help investors to digest information that contributes to Tempest Therapeutics' financial success or failures. It also enables traders to predict the movement of Tempest Stock. The fundamental analysis module provides a way to measure Tempest Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tempest Therapeutics stock.
Tempest | Three Year Return |
Tempest Therapeutics Company Three Year Return Analysis
Tempest Therapeutics' Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Tempest Three Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Tempest Therapeutics is extremely important. It helps to project a fair market value of Tempest Stock properly, considering its historical fundamentals such as Three Year Return. Since Tempest Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tempest Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tempest Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
Tempest Return On Tangible Assets
Return On Tangible Assets |
|
Based on the latest financial disclosure, Tempest Therapeutics has a Three Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Tempest Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tempest Therapeutics' direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics of similar companies.Tempest Therapeutics is currently under evaluation in three year return category among its peers.
Tempest Fundamentals
| Return On Equity | -2.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 37.08 M | ||||
| Shares Outstanding | 43.64 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 23.02 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 3.62 X | ||||
| EBITDA | (28.78 M) | ||||
| Net Income | (29.49 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 20.66 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | (27.36 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 17 | ||||
| Beta | -2.78 | ||||
| Market Capitalization | 41.89 M | ||||
| Total Asset | 51.6 M | ||||
| Retained Earnings | (165.26 M) | ||||
| Working Capital | 30.95 M | ||||
| Net Asset | 51.6 M |
About Tempest Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tempest Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.